Welcome to our dedicated page for Neumora Therapeutics SEC filings (Ticker: NMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neumora Therapeutics, Inc. filings document the regulatory record for a Nasdaq-listed clinical-stage biopharmaceutical company developing therapies that target novel mechanisms of action. The company’s 8-K reports furnish financial results, business updates, corporate presentations, and clinical-development disclosures for programs including navacaprant, NMRA-511, NMRA-898, NMRA-861, and NMRA-215.
Neumora’s SEC filings also cover proxy governance, executive compensation, board and shareholder voting matters, registered common stock, and capital-structure events. Recent disclosure areas include Regulation FD presentations, unregistered equity issuance tied to a loan conversion right, and formal exhibits that describe program plans, financing arrangements, risk statements, and public-company reporting obligations.
Neumora Therapeutics, Inc. has filed a notice of proposed sale of 146,706 shares of its common stock through Merrill Lynch at 225 Liberty Street, New York, with shares to be sold on or about 08/17/2026 on the NASDAQ. The filing lists an aggregate market value of approximately $220,135.18 for these shares and reports 187,895,912 shares of common stock outstanding as a baseline figure. The securities to be sold were acquired through an exercise of employee stock options for 112,686 shares on 08/17/2026 and through vesting of restricted stock unit awards of 24,375 shares on 02/14/2026 and 9,645 shares on 02/14/2025 under the issuer’s equity compensation plan.
Neumora Therapeutics, Inc. reported continuing losses and liquidity pressure for the quarter ended June 30, 2026. Net loss was $43.1 million for the quarter and $96.5 million for the first half of 2026, driven by research and development expenses of $67.9 million and general and administrative expenses of $27.2 million over six months.
Cash and cash equivalents were $116.8 million at June 30, 2026, down from $182.5 million at year-end, with $85.9 million used in operating activities in the first half. Management concluded that existing cash will not fund operating plans for at least 12 months, raising substantial doubt about the company’s ability to continue as a going concern. Neumora discontinued development of navacaprant in major depressive disorder following Phase 3 results and is now focusing on NMRA-511 for agitation in Alzheimer’s disease, NMRA-898 for schizophrenia, and NMRA-215 for obesity and cardiovascular risk. The company has a $60.0 million term loan outstanding, interest-only through April 2029, with a minimum liquidity covenant effective July 1, 2026 and a final maturity in May 2029.
Neumora Therapeutics, Inc. reported financial results for the quarter ended June 30, 2026 and outlined key pipeline and leadership developments. The company had $116.8 million in cash and cash equivalents and expects this to fund its operating plan into the third quarter of 2027. Research and development expenses were $29.3 million, down from $38.7 million a year earlier, and general and administrative expenses were $12.9 million, down from $15.3 million. Net loss for the quarter was $43.1 million compared with $52.7 million in the prior-year period.
Neumora reported favorable pre-clinical data for NMRA-215 and plans to submit an IND in the fourth quarter of 2026 and start a Phase 1 study by year-end 2026. It plans Phase 1 data for NMRA-898 in the second half of 2026 and MAD expansion data plus Phase 2 initiation for NMRA-511 in Alzheimer’s disease agitation by the end of 2026. The company also announced a leadership transition effective August 14, 2026, with Joshua Pinto, Ph.D. becoming president and chief executive officer and joining the Board, while co-founder Paul L. Berns becomes Executive Chair.
Neumora Therapeutics, Inc. reported favorable pre-clinical toxicology results for NMRA-215, a highly brain-penetrant, oral NLRP3 inhibitor being developed for obesity and cardiometabolic disorders. In a repeat 13-week rat toxicology study of 162 animals, no unexpected in-life adverse findings were observed.
The repeat study followed an earlier 13-week rat study in which 5 of 142 animals showed unexpected adverse findings; after a for-cause audit and review of all rat and dog toxicology data, the company continues to believe those findings were not related to NMRA-215. Based on the toxicology package and pre-clinical efficacy data in a diet-induced obesity mouse model, Neumora plans to submit an IND for NMRA-215 in the fourth quarter of 2026 and to initiate a Phase 1 study by the end of 2026.
Neumora Therapeutics reported that its Phase 3 KOASTAL‑2 and KOASTAL‑3 trials of navacaprant in major depressive disorder failed to achieve statistical significance on primary or key secondary endpoints, and the company is discontinuing development of navacaprant. KOASTAL‑2 and KOASTAL‑3 enrolled 430 and 422 adult patients, respectively, and showed similar or numerically worse depression score changes versus placebo.
Neumora is implementing a workforce reduction of approximately 35%, expecting about $10 million in annualized cost savings, partially offset by about $2 million in one‑time restructuring costs in the second quarter of 2026. Following these changes, the company expects its current cash and cash equivalents to provide runway into the third quarter of 2027 while it focuses on NMRA‑511 in Alzheimer’s disease agitation, NMRA‑898 in schizophrenia and NMRA‑215 in cardiometabolic disease. Neumora also entered a Third Amendment to its Loan and Security Agreement, extending the interest‑only period and revising a minimum liquidity covenant tied to milestones and market capitalization.
Neumora Therapeutics, Inc. director and 10% owner Kristina Burow received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.86 per share and expire on May 26, 2036.
According to the grant terms, 100% of the shares subject to the option vest on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next annual meeting following that date. After this grant, the filing shows 80,000 derivative securities held directly.
Neumora Therapeutics director Matthew K. Fust received a grant of stock options covering 80,000 shares of Common Stock. The options have an exercise price of $1.86 per share and expire on May 26, 2036. All 80,000 shares vest on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next Annual Meeting after that date. Following this compensation award, Fust holds 80,000 derivative securities directly.
Neumora Therapeutics director David Piacquad received a grant of stock options for 80,000 shares of Common Stock at an exercise price of $1.86 per share. All 80,000 options vest 100% on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next Annual Meeting following that date, and expire on May 26, 2036.
Neumora Therapeutics, Inc. director Alaa Halawa received a grant of stock options covering 80,000 shares of common stock. The options carry an exercise price of $1.86 per share and expire on May 26, 2036. All 80,000 option shares vest on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next annual meeting following that date.
Neumora Therapeutics director Ho Maykin received a grant of stock options for 80,000 shares of Common Stock. The options have an exercise price of $1.86 per share and expire on May 26, 2036. All 80,000 options vest 100% on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next Annual Meeting following that date.